Short Takes: July 11, 2025

Number 6 will blow your mind! We just love* the clickbait headline from Everyday Health: “9 Signs Your Compounded GLP-1 Supplier Is Shady.” Why not “9 Signs Your Compounded GLP-1 Supplier Is Safe”? Yeah, we know. 

This week in Compounding Interests. The FDA’s guidance document for compounding animal drugs — GFI #256 — is, Scott explains in this week’s edition, “a perfect case study in federal overreach.” It undermines veterinary expertise, adds unnecessary bureaucracy, and restricts access to animal medications for, frankly, no good reason. (And that “overreach” part? As we explain in our blueprint for reducing compounding regulation, the FDA has no statutory authority over veterinary compounding in the first place.)

38 ways to improve veterinary compounding. “The FDA lacks the necessary flexibility needed to keep pace with innovation and modernization in the animal health industry.” That’s the first line of the Reagan-Udall Foundation’s recommendations for the agency — 38 recommendations covered in a 21-page document that provides a detailed, evidence-based justification for each, from “Modernize the regulatory pathways for animal health products” to “strengthen the Veterinary Medicine Loan Repayment Program” and a lot more. Read the PDF to get a 30,000-ft. (9,144 m) view of what’s facing the veterinary side of the profession.

Media buy still paying off. It’s only been a week since we told you about our first results from our Big Beautiful Media Buy promoting our Blueprint. In just that time we went from having about 8,500 visits to the landing page to having 11,575 (a 36.2% jump). And instead of just 625 downloads of the Blueprint itself, we’re now up to 738, mostly thanks to our ad buys on LinkedIn and our sponsorship of Axios Vitals.

*That's sarcasm.